ContributorsPublishersAdvertisers

#Small Molecule

Liminal Biosciences provides update on research programs

Liminal BioSciences (NASDAQ:LMNL) provided updates on its research and development priorities for 2022. The company said that in 2021 following analysis of preliminary pharmacokinetic data from its Phase I MAD trial, it announced that it would not be progressing the development of fezagepras to treat idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia.
MEDICAL & BIOTECH
Picture for Liminal Biosciences provides update on research programs
clinicaltrialsarena.com

UNION’s orismilast enters Phase IIb and a crowded small molecule market

If approved, orismilast would be the second oral phosphodiesterase-4 inhibitor to enter the plaque psoriasis space. On 13 January, UNION Therapeutics registered a Phase IIb, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of the phosphodiesterase-4 (PDE4) inhibitor, orismilast, in adults with moderate-to-severe plaque psoriasis (PsO). Orismilast (20mg, 30mg and 40mg) is expected to be tested in 200 subjects, with its efficacy being measured by percentage change from baseline in Psoriasis Activity and Severity (PASI) scores at week 16. The proportions of patients achieving a 75% reduction in symptoms (PASI75) and Investigator’s Global Assessment score improvement are currently listed as key secondary endpoints. This trial, NCT05190419, is expected to begin in both the US and Europe. If approved, orismilast would be the second oral PDE4 inhibitor to enter the space and the third member of the class overall, trailing behind Amgen’s Otezla (apremilast) and Arcutis’ topical PDE4 inhibitor roflumilast, the latter of which is expected to gain approval later this year.
MEDICAL & BIOTECH
Picture for UNION’s orismilast enters Phase IIb and a crowded small molecule market
drug-dev.com

Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), recently announced the launch of its newly enhanced corporate website encapsulating the company’s full suite of Bench to Market™ services and its position as the preferred partner for the development and manufacture of oral BCS-III and BCS-IV drug products, including oral peptides, peptidomimetics, and small molecules. The redesigned website may be accessed via http://www.EnterisBioPharma.com.
MEDICAL & BIOTECH
Picture for Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services
TRENDING TOPICS
modernreaders.com

SpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6.1%

Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) were down 6.1% during trading on Wednesday . The stock traded as low as $54.46 and last traded at $54.46. Approximately 14,788 shares were traded during trading, a decline of 97% from the average daily volume of 563,991 shares. The stock had previously closed at $57.99.
STOCKS
jneurosci.org

Expression of Concern: Wang et al., “Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A”

JNeurosci is publishing an Expression of Concern for the article, “Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A,” by Hoau-Yan Wang, Kalindi Bakshi, Maya Frankfurt, Andres Stucky, Marissa Goberdhan, Sanket M. Shah, and Lindsay H. Burns, which appeared on pages 9773–9784 of the July 18, 2012 issue. The editors have been made aware of concerns about Western blots in this study, including those published with the article's erratum (Wang et al., 2021). These and other concerns are currently under investigation by the academic authorities at the City University of New York (CUNY). JNeurosci will await the outcome of that investigation before taking further action.
SCIENCE
drug-dev.com

FORMULATION FORUM – Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals

Lipid nanoparticles (LNPs) are nano-sized particles that are mainly composed of lipids. Traditionally, LNPs are referred to as liposomes, lipoplexes, solid lipid nanoparticles, nanostructured lipid nanoparticles, microemulsions, and nanoemulsions, which are mainly used in the delivery of small molecules and peptides. Recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
SCIENCE
Medagadget.com

Small Molecule API Market Size, Rising Impact of COVID-19, Outlook, Opportunities, Key Players, Growth, Competitive Landscape, Trends and Forecast to 2027

Market Research Future (MRFR) presumes that the small molecule API market will be advancing at a rate of 7.0% from 2020 to 2027. Also, the total value by the end of 2027 Small Molecule API Market is projected to be around USD 279,687.1 Million, believes Market Research Future. Small molecules...
INDUSTRY
liverpoolstudentmedia.com

Global Small Molecule Cancer Drug Market Scope 2022-2028 Industry Growth, Business Opportunity, and Leading Players

The latest updated report of Small Molecule Cancer Drug Market by In4Research provides key information by Top Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast 2022-2028. The Market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Global Small Molecule Cancer Drug Market. The decision-makers or Industry professionals in Small Molecule Cancer Drug business can use this report to plan effective growth strategies and prepare for future challenges beforehand.
CANCER
cancerletter.com

Cullinan Oncology, Mount Sinai partner to advance novel small molecule immune modulators

Cullinan Oncology Inc. and Icahn School of Medicine at Mount Sinai entered into a collaboration agreement to develop novel small molecule immune modulators. This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor kinase 1 (HPK1), a key regulator of immune cell activation and a high-priority target in immune-oncology. The collaboration aims to accelerate the development of novel, best-in-class HPK1 degraders that stimulate robust anti-tumor immunity.
ECONOMY
gettotext.com

How a small molecule repairs the brain

16:00 How a small molecule repairs the brain The hope of brain research is currently based on the synthetic substance ISRIB. In mice it regenerates injured and demented brains. 01/09/2022 4:00 p.m. 21 comments MIT Technology Review.
SCIENCE
drugtargetreview.com

Episode 5 – Small molecule screening with Dr Sheraz Gul, Fraunhofer Institute & Dr John Fuller, Beckman Coulter

In this latest episode, we discuss how small molecule discovery can be automated and how this process saves researchers time and money. In this episode of Drug Target Review’s podcast, sponsored by Beckman Coulter, Deputy Editor Victoria Rees speaks with Dr Sheraz Gul, Head of Drug Screening and Compound Repurposing at the Fraunhofer Institute and Dr John Fuller, Global Commercial Product Manager at Beckman Coulter about the automation of small molecule discovery and development.
INDUSTRY
tickerreport.com

Rain Therapeutics (NASDAQ:RAIN) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research cut shares of Rain Therapeutics (NASDAQ:RAIN) from a hold rating to a sell rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies which target oncogenic drivers. The company’s lead product candidate includes RAIN-32. Rain Therapeutics Inc. is based in NEWARK, Calif. “
STOCKS
etfdailynews.com

Pharvaris (NASDAQ:PHVS) Shares Gap Up to $15.98

Pharvaris (NASDAQ:PHVS) shares gapped up prior to trading on Friday . The stock had previously closed at $15.98, but opened at $18.85. Pharvaris shares last traded at $18.85, with a volume of 10 shares. Separately, Zacks Investment Research downgraded Pharvaris from a “hold” rating to a “sell” rating in a...
STOCKS
biophotonics.world

The RNA targeting small molecule therapies market

In the recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; as a result, a number of industry players have developed their proprietary technologies for direct and indirect RNA targeting and are actively engaged in the discovery and development of therapies against a wide range of therapeutic disorders.
ECONOMY

BioCryst begins enrollment in the REDEEM-1 Pivotal Study to evaluate BCX9930 as an oral monotherapy for patients with PNH | Small molecules

BioCryst begins enrolling patients in the REDEEM-1 Pivotal Study to evaluate BCX9930 as an oral monotherapy for patients with PNH. Details Category: Small Molecules Posted on Saturday, January 08th 2022 17:28 Hits: 187. RESEARCH TRIANGLE PARK, NC, USA I January 07, 2022 IBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the...
MEDICAL & BIOTECH
gastroenterologyadvisor.com

Efficacy of an Investigational Small Molecule for Pain After Colorectal Surgery

Treatment with VVZ-149, a small molecule that inhibits the glycine transporter type 2 and the serotonin receptor 5-hydroxytryptamine 2A, resulted in a nonsignificant reduction of postoperative pain 8 hours after colorectal surgery. A post hoc analysis, however, suggested it may be beneficial in patients with negative affect who have higher postoperative opioid use. These findings were published in Journal of Clinical Anesthesia.
HEALTH

BioTools Announces A Collaboration With Schrödinger Aimed At Accelerating The Discovery And Development Of Chiral Small Molecule Therapeutics

JUPITER, Fla., Jan. 7, 2022 /PRNewswire/ -- BioTools, the pioneer in vibrational circular dichroism (VCD) technology and provider of proprietary instrumentation and analytical services for structure elucidation of chiral molecules, announces a collaboration with Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, to help chemists expedite the determination of the critical three-dimensional stereo structure.
TECHNOLOGY
YOU MAY ALSO LIKE